Citadel Advisors
AVNR

Citadel Advisors’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Citadel Advisors’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-30,700
Closed -$520K – 9290
2014
Q4 		$520K Sell
30,700
-79,700
-72% -$1.12M ﹤0.01% 4676
2014
Q3 		$1.32M Buy
110,400
+81,000
+276% +$553K ﹤0.01% 3364
2014
Q2 		$166K Sell
29,400
-41,800
-59% -$193K ﹤0.01% 5761
2014
Q1 		$261K Buy
71,200
+16,800
+31% +$64K ﹤0.01% 5193
2013
Q4 		$183K Buy
54,400
+18,300
+51% +$75.6K ﹤0.01% 5121
2013
Q3 		$153K Buy
36,100
+25,300
+234% +$120K ﹤0.01% 5006
2013
Q2 		$50K Buy
+10,800
New +$37.1K ﹤0.01% 5680

Citadel Advisors's AVNR Position: Q4 2014 in Review

Citadel Advisors sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 1,691,547 shares — an estimated $23.8M sold.

Citadel Advisors first reported a position in AVNR in Q2 2013 and held it in 6 quarters. The position peaked at $20.2M in Q3 2014. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

  • Citadel Advisors reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
  • Citadel Advisors sold 1,691,547 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $23.8M.
  • Citadel Advisors first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 6 quarters.
  • Citadel Advisors's AVANIR PHARMACEUTICALS, INC CL A position peaked at $20.2M in Q3 2014.
  • 166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on Citadel Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.